2026/02/02 by Vivek Y. Reddy, Elaine Hylek, Alan John Camm +14
Medicine · #Atrial Fibrillation Management and Outcomes #Cardiovascular Disease and Adiposity #Cardiovascular Function and Risk Factors
paper · doi:10.1016/j.ahj.2026.107367
• CATALYST compares Amulet LAAO vs NOACs in AF patients at elevated stroke risk. • Three co-primary endpoints assess stroke, systemic embolism, CV death, and bleeding. • Post-LAAO care includes short DAPT and TEE/CT imaging for contemporary practice. • Results may support LAAO as a first-line alternative to long-term NOACs. Both percutaneous left atrial appendage occlusion (LAAO) and non-vitamin K antagonist oral anticoagulants (NOACs) are noninferior to warfarin for stroke prevention in high-risk patients with atrial fibrillation (AF). However, there is limited data comparing LAAO with NOACs. The CATALYST trial compares a dual-seal LAAO device (Amplatzer™ Amulet™) to NOACs in AF patients indicated for thromboprophylaxis. CATALYST is a prospective, multicenter, randomized controlled, open-label trial with an adaptive statistical design. Up to 2,650 AF patients with CHA 2 DS 2 -VASc score ≥2 (men) or ≥3 (women) will be randomly assigned to LAAO or NOAC at 123 global sites. Patients randomized to NOACs take the appropriate labeled dose with compliance monitored at each visit, while LAAO patients receive dual antiplatelet therapy followed by aspirin monotherapy for ≥12 months post-implant. Patients are followed through 5 years, with post-implant cardiac imaging at 3- and 12-months. There are three co-primary endpoints: (1) ischemic stroke, systemic embolism, or cardiovascular death through 2 years, tested for noninferiority; (2) major or clinically relevant non-major bleeding through 2 years, tested for superiority; and (3) ischemic stroke or systemic embolism through 3 years, tested for noninferiority. The following secondary endpoints will be tested if the primary endpoints are met: (1) all-bleeding, tested for noninferiority; (2) followed by testing for superiority; (3) disabling or fatal strokes, tested for superiority; all through 2 years. CATALYST is evaluating the safety and effectiveness of a dual seal LAAO device compared to NOACs in patients with AF at increased risk of stroke. URL https://clinicaltrials.gov ; Unique Identifier NCT04226547